Novo Nordisk has initiated legal action against Eli Lilly in a U.S. federal court, accusing its competitor of running deceptive advertising campaigns for its blockbuster diabetes and weight-loss medications. The lawsuit, filed in the U.S. District Court for the District of New Jersey, alleges violations of federal and state false advertising and unfair competition laws, including the Lanham Act.
Allegations of Misleading Comparisons
According to the complaint, Eli Lilly's direct-to-consumer advertisements for Zepbound and Mounjaro create a false impression of superior efficacy by comparing Lilly's products with lower-dose versions of Novo Nordisk's Wegovy and Ozempic. Novo Nordisk contends that these ads omit information about higher-dose formulations that have since received FDA approval, thereby misleading consumers.
Specifically, Novo Nordisk alleges that Lilly's ads rely on outdated clinical trials that compare the highest doses of Zepbound with lower doses of Wegovy, rather than the latest FDA-approved 7.2 mg injectable Wegovy dose. The FDA approved this higher dose in March 2026, and Novo Nordisk states it demonstrated an average body weight reduction of approximately 19%, or about 47 pounds. The company also notes that no head-to-head clinical trial has compared the highest approved doses of Zepbound and Wegovy, making broader superiority claims unfounded.
In the diabetes segment, Novo Nordisk claims Lilly compares the highest approved dose of Mounjaro (15 mg) with Ozempic's 1 mg dose, despite the FDA approving a 2 mg maintenance dose of Ozempic over four years ago. The lawsuit argues that these comparisons are inherently misleading because they do not reflect currently available treatment options.
Legal Remedies Sought
Novo Nordisk is seeking a permanent injunction requiring Eli Lilly to halt the contested advertisements across all platforms and to run a corrective advertising campaign. The company is also demanding damages, including any profits Lilly generated through the allegedly misleading ads. Novo Nordisk states that it previously sent a cease-and-desist letter to Lilly, which was ignored, and that it intends to seek a preliminary injunction if the ads are not voluntarily withdrawn.
“As new and more effective treatment options become available, people deserve accurate information that reflects the latest scientific evidence and helps them make informed care decisions,” said John F. Kuckelman, Senior Vice President and Group General Counsel at Novo Nordisk, in a statement. “Healthcare companies have a responsibility to keep their public claims accurate and current — ineffective, fine-print disclaimers do not fix the misleading impression created by major national campaigns.”
Intensifying Competition in the Obesity Drug Market
The lawsuit underscores the escalating rivalry between Novo Nordisk and Eli Lilly in the rapidly expanding obesity drug market. Both companies have approved products in this space, with Lilly currently leading across the combined diabetes and obesity treatment markets. However, Novo Nordisk has gained ground with its oral Wegovy weight-loss pill, which launched in the U.S. in January, ahead of Lilly's oral treatment introduced in April.
This legal battle adds a new dimension to the competition, as both companies vie for market share in a sector projected to grow significantly. Investors should monitor the outcome, as it could impact advertising strategies and market positioning for both firms. For more on related market movements, see AtaiBeckley Surges 115% on Eli Lilly's $3.8B Acquisition Deal and Apple Reclaims World's Most Valuable Company Title from Nvidia as AI Strategy Gains Traction.
This article is for informational purposes only and does not constitute financial advice.
